Lilly, BMS win broader use of Erbitux in head and neck cancer
This article was originally published in Scrip
Executive Summary
The US FDA approved Lilly's and Bristol-Myers Squibb's Erbitux (cetuximab) in combination with chemotherapy to treat patients with metastatic head and neck cancer.